Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Ardelyx clinical trials
The registry lists 29 studies whose lead sponsor is Ardelyx. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 22, 2026.
Keep track of what changes. Save the Ardelyx studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Ardelyx.
- Ardelyx29 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-CEnrolling by invitationNCT05905926Phase 3
- A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in AdultsRecruitingNCT07382167Phase 3
- Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 YearsCompletedNCT05643534Phase 3
- 4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 YrsCompletedNCT06553547Phase 2
- An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating FemalesCompletedNCT06203444Phase 1
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisCompletedNCT03427125Phase 3
- A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HPCompletedNCT03988920Phase 4
- Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of HyperphosphatemiaCompletedNCT04549597Phase 4
- Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder TherapyCompletedNCT03824587Phase 2/3
- A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of HyperkalemiaCompletedNCT04780841Phase 2
- Dose Finding Study to Treat High Phosphate Levels in the Blood.CompletedNCT02081534Phase 2
- A Long-Term Safety Study of Tenapanor for the Treatment of IBS-CCompletedNCT02727751Phase 3
- An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)CompletedNCT02675998Phase 3
- Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on HemodialysisCompletedNCT01764854Phase 2
- A Study in CKD Patients With Type 2 Diabetes Mellitus and AlbuminuriaCompletedNCT01847092Phase 2
- A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-CCompletedNCT02686138Phase 3
- A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-CCompletedNCT02621892Phase 3
- The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)CompletedNCT01923428Phase 2/3
- A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of HyperkalemiaTerminatedNCT03018067Phase 2
- A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)CompletedNCT01340053Phase 2
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy VolunteersCompletedNCT02819687Phase 1
- Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy VolunteersCompletedNCT02796131Phase 1
- AZD1722 Open Label, Absorption Distribution Metabolism and Excretion StudyCompletedNCT02063386Phase 1
- To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy VolunteersCompletedNCT02140268Phase 1
- To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy VolunteersCompletedNCT02140281Phase 1
- D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy SubjectsCompletedNCT02226783Phase 1
- A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722CompletedNCT02346890Phase 1
- A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 FormulationsCompletedNCT02249936Phase 1
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese SubjectsCompletedNCT02176252Phase 1